Regional Clinical Oncological Dispensary

Velikiy Novgorod, Russia

Regional Clinical Oncological Dispensary

Velikiy Novgorod, Russia

Time filter

Source Type

Bocharov A.V.,Regional Clinical Hospital | Cherenkov V.G.,Regional Clinical Oncological Dispensary | Ukhanov A.P.,Municipal Clinical Hospital No 1 | Chentsov V.I.,Regional Clinical Hospital
Voprosy Onkologii | Year: 2011

Our study was concerned with the role of ultrasound examination of the lower extremity veins to detect deep venous thrombosis and to evaluate complex prophylaxis of thromboembolism of pulmonary arteries (TEPA). The procedure involved vena cava filter placement in patients with neoplasia and high risk of TEPA as compared with controls receiving conservative therapy alone. A positive correlation was established between surgery and/or polychemotherapy, on the one hand, and higher stage and high risk of TEPA, on the other. Patients with deep venous thrombosis and neoplasia were referred to groups of extremely high risk of that pathology. Angiological history, physical examination and ultrasound check-ups of the lower vein must be carried out in cancer patients. Vena cava filter placement proved to be an effective and safe measure of TEPA prophylaxis. It lowered the risk of lethal outcome in 24 during surgery and polychemotherapy. Lethality rate among controls was 43.5±0.51%.


Vasilchenko I.L.,Regional Clinical Oncological Dispensary | Vinogradov V.M.,The Surgical Center | Pastushenko D.A.,Regional Clinical Oncological Dispensary | Samsonova N.N.,Regional Clinical Oncological Dispensary | Yudin A.L.,Regional Clinical Oncological Dispensary
Voprosy Onkologii | Year: 2011

Results of clinical use of radiosurgical treatment-combination of larynx preservation and pre- and postoperative distant external irradiation -were evaluated. Forty-eight patients with locally advanced laryngeal cancer received single-step individually-tailored tissue application, followed by high-dose brachytherapy. Discriminative function of the larynx was restored in all patients within 2 days involving swallowing disturbances in 8%. Breathing function was restored in 98% within 2 days - 6 months after completion of treatment. Three-year relapse-free survival was 95.8%.

Loading Regional Clinical Oncological Dispensary collaborators
Loading Regional Clinical Oncological Dispensary collaborators